Novadiscovery
Ehud Gelblum serves as a fractional Chief Financial Officer for multiple innovative companies, including Novadiscovery, Cardiosense, and Parsley Health, focusing on advancements in healthcare technology and digital health solutions. Gelblum also holds a senior financial advisory role at Wavely Diagnostics and has been an active member and investor in angel investment groups such as New York Angels and Mid Atlantic Bio Angels since 2018. Previously, Gelblum was the Chief Financial Officer at caresyntax and had interim leadership at UNTUCKit. Educational credentials include a Ph.D. and MSE in Electrical Engineering from Columbia University, alongside a BSE in Finance and Accounting from The Wharton School, and an undergraduate degree in Electrical Engineering from the University of Pennsylvania.
This person is not in any offices
Novadiscovery
novadiscovery is a developer of a drug discovery platform in silico clinical trials designed to de-risk, optimize research and development along with curbing the cost of discovering new drugs. The company's platform uses mathematics and intelligent algorithms to build a community of virtual patients as on-demand digital lab rats, enablingscientists and biotech, pharma companies to predict drug efficacy and create the target combination.